
Sarah McFarlane
Chief Energy Transition Correspondent at Reuters
Chief energy transition correspondent at Thomson Reuters. Any views expressed are my own.
Articles
-
4 days ago |
healtheconomics.com | Sarah McFarlane
AstraZeneca’s experimental drug camizestrant has demonstrated promising results in extending the benefits of initial breast cancer treatment, according to new data presented at the American Society of Clinical Oncology’s annual meeting. The study focused on patients with hormone receptor-positive, HER2-negative advanced breast cancer, which accounts for approximately 70% of breast cancer cases.
-
1 week ago |
healtheconomics.com | Sarah McFarlane
Pfizer is making significant strides towards securing full FDA approval for its Braftovi combination therapy, following a unique accelerated approval less than six months ago. The therapy, which pairs Braftovi with Eli Lilly’s Erbitux and the chemotherapy regimen mFOLFOX6, targets metastatic colorectal cancer (mCRC) patients with a BRAF V600E mutation.
-
1 week ago |
healtheconomics.com | Sarah McFarlane
The U.S. Department of Health and Human Services (HHS) has canceled its contract with Moderna intended to develop mRNA vaccines against potential pandemic avian flu strains. This decision leaves the future of Moderna’s research uncertain, even though the company reported promising early-stage results for its H5 avian influenza vaccine.
-
1 week ago |
healtheconomics.com | Sarah McFarlane
Veru is advancing its muscle-preserving obesity drug, enobosarm, into Phase 3 trials following promising Phase 2 safety results. When combined with Novo Nordisk’s Wegovy, enobosarm showed fewer gastrointestinal side effects such as nausea and heartburn compared to Wegovy alone. Notably, the dose planned for Phase 3 testing demonstrated reduced occurrences of diarrhea and vomiting. However, some participants did experience elevated liver enzymes, which later normalized during the trial.
-
1 week ago |
healtheconomics.com | Sarah McFarlane
The Trump administration has announced new measures to bolster price transparency in healthcare, focusing on stricter compliance and enforcement among hospitals and insurers. The Centers for Medicare & Medicaid Services (CMS) has updated its guidance, requiring hospitals to disclose actual prices of services and requesting public input on ensuring data accuracy.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 345
- DMs Open
- No

#Shell says bye to Dutch HQ, Hello London https://t.co/RHI6BgixGb via @WSJ

#COP26 to spur on international carbon trading https://t.co/OFXYL7mCsF via @WSJ

#COP26 sees standing ovation after more than 190 nations reached a deal to accelerate greenhouse gas emissions cuts https://t.co/lJU6MtyWP2 via @WSJ